Beximco, Eskayef launch Pfizer’s anti-Covid pill | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Friday
July 11, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
FRIDAY, JULY 11, 2025
Beximco, Eskayef launch Pfizer’s anti-Covid pill

Covid-19 in Bangladesh

TBS Report
30 December, 2021, 04:35 pm
Last modified: 30 December, 2021, 10:04 pm

Related News

  • Beximco Pharma's share price plummets 47% since July
  • What Beximco Pharma says to London Stock Exchange about unrest impact
  • Beximco Pharma secures €24.9m for business expansion
  • Beximco Pharma’s revenue surges 12% in July-Dec
  • Beximco Pharma on Forbes list of best companies in Asia

Beximco, Eskayef launch Pfizer’s anti-Covid pill

The medicine showed almost 90% efficacy in preventing hospitalisations and deaths in high-risk patients

TBS Report
30 December, 2021, 04:35 pm
Last modified: 30 December, 2021, 10:04 pm
Beximco, Eskayef launch Pfizer’s anti-Covid pill

Beximco and Eskayef, two leading pharmaceutical companies in the country, have separately announced the launch of Pfizer's oral antiviral medication – Paxlovid – for the treatment of Covid-19.

Beximco Pharmaceuticals Limited will market the drug under the brand name of Bexovid, while Eskayef will market it as Paxovir.

Both companies made their announcements on Thursday after the Directorate General of Drug Administration (DGDA) granted emergency use authorisation for the drug to treat mild-to-moderate Covid-19 patients including adults and children aged 12 years and above.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

Earlier on 22 December, the US Food and Drug Administration (FDA) granted emergency use authorisation to the drug as the first approved oral therapy for Covid-19 treatment.

This novel antiviral pill showed almost 90% efficacy in preventing hospitalisations and deaths in high-risk patients, and recent lab data suggests the drug retains its effectiveness against the fast spreading Omicron variant of the coronavirus. 

The drug is co-packaged with nirmatrelvir and ritonavir tablets.

Nirmatrelvir inhibits a SARS-CoV-2 enzyme to stop the virus from replicating, and ritonavir slows down nirmatrelvir's breakdown to help it remain in the body for a longer period at higher concentrations.

The treatment is given as two tablets of nirmatrelvir and one tablet of ritonavir together twice a day for five days. Bexovid is available by prescription only and should be initiated as soon as possible after diagnosis of Covid-19 and within five days of symptom onset. 

Nazmul Hassan, managing director of Beximco Pharmaceuticals, commented, "Having previously introduced the world's first generic Covid-19 treatments of remdesivir and molnupiravir, we are pleased to add this breakthrough therapy to our portfolio.

"It is further testament to our commitment to making affordable treatments accessible as soon as possible. As data continues to emerge demonstrating the effectiveness of nirmatrelvir and ritonavir against the fast-emerging Omicron variant, we believe that Bexovid has the potential to be a powerful tool in combating the ongoing pandemic."

Simeen Rahman, managing director and CEO of Eskayef Pharmaceuticals Limited, said, "Since the beginning of the pandemic Eskayef has been trying to deliver drugs, which are effective for treatment against the coronavirus. This new drug is a part of that ongoing effort."

Earlier on 9 November, The DGDA granted Beximco, Square, Eskayef and Renata the approval for the production and marketing of molnupiravir, the first-ever Covid-19 pill developed by US drugmaker Merck & Co Inc and Ridgeback Biotherapeutics. Molnupiravir is now available in the country's domestic market.

Bangladesh / Top News / Health

Paxlovid / Beximco Pharmaceuticals Limited

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Kunming rising: China's emerging healthcare hub draws Bangladeshi patients
    Kunming rising: China's emerging healthcare hub draws Bangladeshi patients
  • Abul Barkat at Dhaka Metropolitan Magistrate Court on 11 July 2025. Photo: TBS
    Economist Abul Barkat sent to jail in Tk297cr embezzlement case
  • News of The Day, 11 JULY 2025
    News of The Day, 11 JULY 2025

MOST VIEWED

  • Photo: Mohammad Minhaj Uddin/TBS
    SSC, equivalent results: Pass rate drops to 68.45%, GPA-5 also declines
  • In terms of stream of education, girls maintained their excellence as well. Photo: TBS
    SSC 2025: Girls dominate boys by over 5%
  • Govt vehicle purchase, foreign trip, new building construction banned: Finance ministry
    Govt vehicle purchase, foreign trip, new building construction banned: Finance ministry
  • Students sit for SSC exam at Motijheel Girls' High School on 10 April 2025. Photo: Mehedi Hasan/TBS
    SSC exam results out: Here's how you can check online and via SMS
  • The overall pass rate across all boards this year, 68.45%, is significantly lower than last year's. Photo: Focus Bangla
    SSC 2025: Rajshahi board records highest pass rate, Barishal lowest
  • Representational image. Photo: Collected
    35% tariff: Bangladesh, US 'agree on most issues' as first day of talks ends

Related News

  • Beximco Pharma's share price plummets 47% since July
  • What Beximco Pharma says to London Stock Exchange about unrest impact
  • Beximco Pharma secures €24.9m for business expansion
  • Beximco Pharma’s revenue surges 12% in July-Dec
  • Beximco Pharma on Forbes list of best companies in Asia

Features

Kunming rising: China's emerging healthcare hub draws Bangladeshi patients

Kunming rising: China's emerging healthcare hub draws Bangladeshi patients

1h | Panorama
Photo: Collected/BBC

What Hitler’s tariff policy misfire can teach the modern world

22h | The Big Picture
Illustration: TBS

Behind closed doors: Why women in Bangladesh stay in abusive marriages

1d | Panorama
Purbachl’s 144-acre Sal forest is an essential part of the area’s biodiversity. Within it, 128 species of plants and 74 species of animals — many of them endangered — have been identified. Photo: Syed Zakir Hossain/TBS

A forest saved: Inside the restoration of Purbachal's last Sal grove

1d | Panorama

More Videos from TBS

Trump-Netanyahu in new strategy on Gaza issue

Trump-Netanyahu in new strategy on Gaza issue

59m | TBS World
Shocking science: why birds stay safe on electricity lines

Shocking science: why birds stay safe on electricity lines

1h | TBS Stories
Threat of 35 percent tariff on Canadian goods

Threat of 35 percent tariff on Canadian goods

2h | TBS World
Israel ready to strike back if Iran threatens: Katz

Israel ready to strike back if Iran threatens: Katz

4h | TBS World
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net